Journal profile · Pharmacology & Pharmacy
Cancer Chemotherapy and Pharmacology
ISSN 0344-5704 · eISSN 1432-0843 · Springer Berlin Heidelberg · UNITED STATES · Monthly · Founded 1978
Cancer Chemotherapy and Pharmacology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.53; hybrid open access; APC about USD 4,390; median 118 days to acceptance (107 articles, last 24 months); community-reported acceptance: easy; 112 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Chemotherapy and Pharmacology is published by Springer Berlin Heidelberg and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms and Colorectal Cancer Treatments and Studies, together about 29.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Chemotherapy and Pharmacology reports preclinical and or clinical pharmacology of anticancer drugs, covering pharmacokinetics and pharmacodynamics aspects. The journal publishes results recorded in the following areas:- Pharmacokinetics- Pharmacodynamics- Drug interactions- Exposure response relationships- Predictors of response/toxicity Cancer Chemotherapy and Pharmacology is an online-only journal and its print ISSN (0344-5704) is ceased. Editors-In-Chief Jan Hendrik Beumer PharmD, PhD, DABT Étienne Chatelut PharmD, PhD View all editors
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Jan HendrikPublisher website
Editorial board by country: none in mainland China; most named United States 9, France 5, United Kingdom 4, Netherlands 2, Japan 1 (24 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Treatment and PharmacologyMedicine11.3%
- Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology10.5%
- Colorectal Cancer Treatments and StudiesMedicine7.6%
- Lung Cancer Research StudiesMedicine7.1%
- Lung Cancer Treatments and MutationsMedicine6.8%
- Chemotherapy-induced organ toxicity mitigationMedicine6.5%
- Drug Transport and Resistance MechanismsMedicine5%
- Chemotherapy-induced cardiotoxicity and mitigationMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, AGRICOLA, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.53LetPub ·
- Impact factor (publisher) 2025
- 2.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.7Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.75LetPub ·
- h-index
- 100LetPub ·
- h-index
- 155OpenAlex ·
- i10-index
- 6,562OpenAlex ·
- 2-year mean citedness
- 2.32OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 34.66%LetPub ·
Volume
- Articles per year
- 103LetPub ·
- Downloads per year (publisher) 2025
- 1,000,000Publisher website ·
Articles by year OpenAlex count · 9,837 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 110 | 47 | 44 |
| 2025 | 112 | 42 | 250 |
| 2024 | 109 | 56 | 474 |
| 2023 | 126 | 54 | 1,026 |
| 2022 | 125 | 52 | 1,332 |
| 2021 | 173 | 69 | 2,694 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
118 daysMedian, submission to acceptance · P25–P75 84 days – 142 days
- Acceptance to online
- median 19 days (107 articles)
- Submission to online
- median 141 days
- Sample
- 107 articles with submission and acceptance dates (131 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2.5 monthsLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,390 / EUR 3,690 / GBP 2,890 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted10
- brief reportCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- case reportCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- correspondenceCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- editorialCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- opinionCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- original researchCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- researchthe Research article type denotes a complete, comprehensive report of original research. Suggested limits: 5000 words, 45 references, 6 figures/tables.Length not stated
- research articleCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- reviewCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
- surveyCCAP will consider for publication the following articles: Correspondence: The Correspondence article type denotes arresting and timely comments on material pub…Length not stated
Policy excerpts from the journal's websiteAI use, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Conflicts of interest Disclosure of Potential Conflicts of Interest
Authors must disclose all relationships or interests that could influence or bias the work. Although an author may not feel there are conflicts, disclosure of relationships and interests affords a more transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interests is a perspective to which the readers are entitled and is not …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Cancer Chemotherapy and Pharmacology, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Excludes studies on biological extracts that are not a single chemical species with a fully defined chemical structure. Model summary
CCAP does not consider: Studies that describe the effects of biological extracts, i.e. normally natural products, where the extracts is not a single chemical species with a fully defined chemical structure.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Berlin Heidelberg
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1978
- ISSN
- 0344-5704
- Electronic ISSN
- 1432-0843
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Chemotherapy and Pharmacology
What CAS zone is Cancer Chemotherapy and Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Chemotherapy and Pharmacology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Chemotherapy and Pharmacology?
The latest impact factor listed by LetPub is 2.53; CiteScore 4.6, h-index 155.
How long does peer review take at Cancer Chemotherapy and Pharmacology?
Based on the dates recorded on 107 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 118 days (interquartile range 84–142 days); authors report an average review time of about 2.5 months; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Chemotherapy and Pharmacology?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Chemotherapy and Pharmacology based?
Of the 24 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (9), France (5) and United Kingdom (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Chemotherapy and Pharmacology?
According to LetPub and DOAJ records, Cancer Chemotherapy and Pharmacology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Cancer Chemotherapy and Pharmacology open access, and what is the APC?
Cancer Chemotherapy and Pharmacology is a hybrid journal. For open-access publication: APC about USD 4,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .